Pilot study suggests Parkinson’s disease progression can be slowed

Pilot study suggests Parkinson’s disease progression can be slowed

Publication date: Jun 30, 2020

Credit: Vanderbilt University Medical Center Deep Brain Stimulation (DBS) implanted in early stage Parkinson’s disease decreases the risk of disease progression and the need to prescribe multiple drugs to patients simultaneously, according to a five-year outcomes study of 30 patients released in the July 2020, issue of Neurology, the medical journal of the American Academy of Neurology.

The journal released a Classification of Evidence statement along with the study stating that it provides “Class II evidence that DBS implanted in early stage Parkinson disease decreases the risk of disease progression and polypharmacy compared to optimal medical therapy alone. “

With this pilot study, we’ve shown that if DBS is implanted early it’s likely to decrease the risk of progression, and if this is borne out in our larger study it would be a landmark achievement in the field of Parkinson’s disease,” said senior author David Charles, MD, professor and vice-chair of Neurology at Vanderbilt University Medical Center (VUMC).

After five years, the patients who received optimal drug therapy only but not surgery in early-stage Parkinson’s had five-fold greater odds of experiencing worsening of their rest tremor, a hallmark of this disease, as compared to patients who received early DBS in addition to drug therapy.

“Patients who were randomized to receive early optimal drug therapy had 15-fold greater odds of needing multiple types of Parkinson’s disease medications,” said project leader Mallory Hacker, Ph. D., MSCI, assistant professor of Neurology at VUMC.

Concepts Keywords
Battery Patient multi site
Bradykinesia Drug therapy
Brain Surgery
Collarbone Drug therapy surgery
DBS Polypharmacy
Deep Brain Stimulation Medicine
Drug Therapy Medical technology
Fair Dealing Medical devices
FDA Clinical medicine
Heart Pacemaker Neuroprosthetics
MSCI Neurotechnology
Neurodegenerative Disorder Electrotherapy
Neurology Neurosurgical procedures
Neurons Deep brain stimulation
Pacemaker Artificial cardiac pacemaker
Parkinson Parkinson
Randomized Clinical Trial
Statistical Significance
Subthalamic Nucleus


Type Source Name
disease MESH disease progression
disease MESH Parkinson disease
pathway KEGG Parkinson disease
disease MESH neurodegenerative disorder
disease MESH tremor
disease MESH bradykinesia
drug DRUGBANK Isoxaflutole

Leave a Comment

Your email address will not be published. Required fields are marked *